Ignite Creation Date:
2024-05-05 @ 11:04 PM
Last Modification Date:
2024-10-26 @ 10:27 AM
Study NCT ID:
NCT01243502
Status:
COMPLETED
Last Update Posted:
2010-11-18
First Post:
2010-11-17
Brief Title:
A Study to Assess the Pharmacokinetics Safety and Tolerability of CT327 in Healthy Male Volunteers
Sponsor:
Creabilis SA
Organization:
Creabilis SA
Study Overview
Official Title:
A Multiple Dose Placebo Controlled Study to Assess the Pharmacokinetics Safety and Tolerability of Topically Administered CT327 in Healthy Male Volunteers
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
K-252a is a potent inhibitor of nerve growth factor NGF and therefore has the ability to inhibit keratinocyte proliferation K-252a is strongly lipophilic and therefore passes freely into the cell membranes of keratinocytes and accumulates at a systemic level In order to reduce the dermal absorption and reduce the possible long-term systemic toxicity this study will assess a PEGylated derivative of K-252a named CT327 This approach should improve the safety profile of the K-252a molecule while maintaining its activity The primary objective is to assess the safety and tolerability of single and repeat doses of CT327 when applied topically to the skin of healthy male volunteers
The secondary objective is to evaluate the eventual systemic absorption pharmacokinetics PK of CT327 following single and repeat doses in healthy male subjects
The secondary objective is to evaluate the eventual systemic absorption pharmacokinetics PK of CT327 following single and repeat doses in healthy male subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None